HengDong Biotechnology
Latest round
- Series A
Last raised
- Nov 2025
Total raised
- Undisclosed
Investors
- 4
About HengDong Biotechnology
Established in 2021 and based in Zhongshan, China, HengDong Biotechnology dedicated to the development of agonistic antibody drugs with class I drug potential using the company's advanced and proprietary core technology platform for screening, optimization and evaluation of agonistic antibodies. Currently, the company has laid out several pipelines, of which the most leading pipeline will be declared IND in 2023. The company has created a biotechnology platform for developing agonistic antibody drugs and developed agonistic antibodies with mono- and dual-antibody forms, which not only achieve an order of magnitude increase in agonistic activity, but also enhance tumor tissue targeting. The company generates revenue from developing agonist antibody drugs.
Who invested in HengDong Biotechnology
4 investors across 2 rounds
See all investors in HengDong Biotechnology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about HengDong Biotechnology
Who invested in HengDong Biotechnology?
HengDong Biotechnology has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has HengDong Biotechnology raised?
HengDong Biotechnology has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did HengDong Biotechnology last raise money?
HengDong Biotechnology's most recent round on record is a Series A, in Nov 2025.
What does HengDong Biotechnology do?
Established in 2021 and based in Zhongshan, China, HengDong Biotechnology dedicated to the development of agonistic antibody drugs with class I drug potential using the company's advanced and proprietary core technology platform for screening, optimization and evaluation of agonistic antibodies.
Where is HengDong Biotechnology headquartered?
HengDong Biotechnology is headquartered in Zhongshan, China.
Which VCs invest in companies like HengDong Biotechnology?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at HengDong Biotechnology's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like HengDong Biotechnology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.